Published in N Engl J Med on August 07, 2003
Myocardial regeneration by activation of multipotent cardiac stem cells in ischemic heart failure. Proc Natl Acad Sci U S A (2005) 3.93
Altered cellular dynamics and endosteal location of aged early hematopoietic progenitor cells revealed by time-lapse intravital imaging in long bones. Blood (2009) 2.58
Cells expressing early cardiac markers reside in the bone marrow and are mobilized into the peripheral blood after myocardial infarction. Circ Res (2004) 2.50
Retracted Glioma-associated cancer-initiating cells induce immunosuppression. Clin Cancer Res (2010) 2.24
Formation of large coronary arteries by cardiac progenitor cells. Proc Natl Acad Sci U S A (2008) 2.05
Limited restoration of cystic fibrosis lung epithelium in vivo with adult bone marrow-derived cells. Am J Respir Crit Care Med (2005) 2.01
Evidence for tissue-resident mesenchymal stem cells in human adult lung from studies of transplanted allografts. J Clin Invest (2007) 1.87
Fully functional bioengineered tooth replacement as an organ replacement therapy. Proc Natl Acad Sci U S A (2009) 1.82
Fibrosis and diseases of the eye. J Clin Invest (2007) 1.79
Therapeutic potential of vasculogenesis and osteogenesis promoted by peripheral blood CD34-positive cells for functional bone healing. Am J Pathol (2006) 1.75
Multilineage-differentiating stress-enduring (Muse) cells are a primary source of induced pluripotent stem cells in human fibroblasts. Proc Natl Acad Sci U S A (2011) 1.69
Side population in human uterine myometrium displays phenotypic and functional characteristics of myometrial stem cells. Proc Natl Acad Sci U S A (2007) 1.50
Cancer gene therapy using mesenchymal stem cells expressing interferon-beta in a mouse prostate cancer lung metastasis model. Gene Ther (2008) 1.42
A nonhuman primate model of lung regeneration: detergent-mediated decellularization and initial in vitro recellularization with mesenchymal stem cells. Tissue Eng Part A (2012) 1.39
Wnt signaling induces epithelial differentiation during cutaneous wound healing. BMC Cell Biol (2006) 1.39
Long-term myocardial functional improvement after autologous bone marrow mononuclear cells transplantation in patients with ST-segment elevation myocardial infarction: 4 years follow-up. Eur Heart J (2009) 1.34
Endometrial stem cell transplantation restores dopamine production in a Parkinson's disease model. J Cell Mol Med (2011) 1.27
Update on therapeutic vascularization strategies. Regen Med (2009) 1.17
Functional tooth regeneration using a bioengineered tooth unit as a mature organ replacement regenerative therapy. PLoS One (2011) 1.17
Stromal derived factor-1 regulates bone morphogenetic protein 2-induced osteogenic differentiation of primary mesenchymal stem cells. Int J Biochem Cell Biol (2010) 1.17
Fate of bone marrow stem cells transplanted into the testis: potential implication for men with testicular failure. Am J Pathol (2007) 1.14
Molecular evidence for arterial repair in atherosclerosis. Proc Natl Acad Sci U S A (2005) 1.09
Human mesenchymal stem cells abrogate experimental allergic encephalomyelitis after intraperitoneal injection, and with sparse CNS infiltration. Neurosci Lett (2008) 1.07
Exploring the mechanisms regulating regeneration of deer antlers. Philos Trans R Soc Lond B Biol Sci (2004) 1.05
Clinical grade adult stem cell banking. Organogenesis (2009) 1.03
In vivo tracking and comparison of the therapeutic effects of MSCs and HSCs for liver injury. PLoS One (2013) 1.02
Stromal cell-derived factor-1β potentiates bone morphogenetic protein-2-stimulated osteoinduction of genetically engineered bone marrow-derived mesenchymal stem cells in vitro. Tissue Eng Part A (2012) 1.02
Stem cell platforms for regenerative medicine. Clin Transl Sci (2009) 1.01
DiR-labeled Embryonic Stem Cells for Targeted Imaging of in vivo Gastric Cancer Cells. Theranostics (2012) 1.01
Disruption of a Quorum Sensing mechanism triggers tumorigenesis: a simple discrete model corroborated by experiments in mammary cancer stem cells. Biol Direct (2010) 1.00
Stem cells in the trabecular meshwork: present and future promises. Exp Eye Res (2008) 1.00
BMP2 genetically engineered MSCs and EPCs promote vascularized bone regeneration in rat critical-sized calvarial bone defects. PLoS One (2013) 0.98
Stromal cell-derived factor-1β mediates cell survival through enhancing autophagy in bone marrow-derived mesenchymal stem cells. PLoS One (2013) 0.98
Optimized cryopreservation method for human dental pulp-derived stem cells and their tissues of origin for banking and clinical use. Cryobiology (2009) 0.98
Mesenchymal Stem Cell Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis (2015) 0.98
Strategies for therapeutic repair: The "R(3)" regenerative medicine paradigm. Clin Transl Sci (2008) 0.97
Stem cells and repair of lung injuries. Respir Res (2004) 0.96
Biomaterials for craniofacial bone engineering. J Dent Res (2014) 0.96
Cryopreserved dental pulp tissues of exfoliated deciduous teeth is a feasible stem cell resource for regenerative medicine. PLoS One (2012) 0.95
Changes in expression of genes related to cell proliferation in human mesenchymal stem cells during in vitro culture in comparison with cancer cells. J Artif Organs (2006) 0.95
Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. Curr Gene Ther (2009) 0.94
Cross-circulation and cell distribution kinetics in parabiotic mice. J Cell Physiol (2012) 0.94
Autologous bone marrow stem cell intralesional transplantation repairing bisphosphonate related osteonecrosis of the jaw. Head Face Med (2011) 0.93
A comparative analysis of the in vitro effects of pulsed electromagnetic field treatment on osteogenic differentiation of two different mesenchymal cell lineages. Biores Open Access (2013) 0.92
Potential of telomerase activation in extending health span and longevity. Curr Opin Cell Biol (2012) 0.92
The regenerative medicine in oral and maxillofacial surgery: the most important innovations in the clinical application of mesenchymal stem cells. Int J Med Sci (2015) 0.92
Perivascular cells in blood vessel regeneration. Biotechnol J (2013) 0.91
Bone marrow stromal cells, preadipocytes, and dermal fibroblasts promote epidermal regeneration in their distinctive fashions. Mol Biol Cell (2004) 0.91
Ex vivo expansion and pluripotential differentiation of cryopreserved human bone marrow mesenchymal stem cells. J Zhejiang Univ Sci B (2007) 0.91
A porcine model of ischemic heart failure produced by intracoronary injection of ethyl alcohol. Heart Vessels (2010) 0.91
Parkinson's disease and mesenchymal stem cells: potential for cell-based therapy. Parkinsons Dis (2012) 0.89
Clinical impact of circulating CD34-positive cells on bone regeneration and healing. Tissue Eng Part B Rev (2014) 0.88
A role of myocardial stiffness in cell-based cardiac repair: a hypothesis. J Cell Mol Med (2009) 0.88
Circulating mesenchymal stem cells microparticles in patients with cerebrovascular disease. PLoS One (2012) 0.88
Role of stem cells in the management of chronic wounds. Indian J Plast Surg (2012) 0.88
Transformation of human mesenchymal cells and skin fibroblasts into hematopoietic cells. PLoS One (2011) 0.88
Potential contribution of neural crest cells to dental enamel formation. Biochem Biophys Res Commun (2011) 0.87
Stem celltherapy for ischemic heart failure. Tex Heart Inst J (2005) 0.87
Infarcted myocardium-like stiffness contributes to endothelial progenitor lineage commitment of bone marrow mononuclear cells. J Cell Mol Med (2011) 0.87
In situ tissue regeneration: chemoattractants for endogenous stem cell recruitment. Tissue Eng Part B Rev (2013) 0.87
From regenerative dentistry to regenerative medicine: progress, challenges, and potential applications of oral stem cells. Stem Cells Cloning (2014) 0.87
Recent advances in bone regeneration using adult stem cells. World J Stem Cells (2015) 0.86
Human umbilical cord blood stem cells show PDGF-D-dependent glioma cell tropism in vitro and in vivo. Neuro Oncol (2010) 0.86
Comparative analysis of gene transcripts for cell signaling receptors in bone marrow-derived hematopoietic stem/progenitor cell and mesenchymal stromal cell populations. Stem Cell Res Ther (2013) 0.85
Regenerative potentials of the murine thyroid in experimental autoimmune thyroiditis: role of CD24. Endocrinology (2008) 0.85
Organoids and the genetically encoded self-assembly of embryonic stem cells. Bioessays (2015) 0.85
Novel interventional approaches for ALI/ARDS: cell-based gene therapy. Mediators Inflamm (2011) 0.84
Myocardial Regeneration by Exogenous and Endogenous Progenitor Cells. Drug Discov Today Dis Mech (2007) 0.84
Localized SDF-1alpha gene release mediated by collagen substrate induces CD117 stem cells homing. J Cell Mol Med (2008) 0.84
Topical application of autologous adipose-derived mesenchymal stem cells (MSCs) for persistent sterile corneal epithelial defect. Graefes Arch Clin Exp Ophthalmol (2011) 0.84
Therapeutic potential of dental pulp stem cells in regenerative medicine: An overview. Dent Res J (Isfahan) (2014) 0.84
Gene therapy and wound healing. Clin Dermatol (2007) 0.84
Effect of ageing on colonic mucosal regeneration. World J Gastroenterol (2011) 0.83
Mesenchymal stem cells as a gene delivery vehicle for successful islet transplantation. Pharm Res (2011) 0.83
Cell therapy for the diseased liver: from stem cell biology to novel models for hepatotropic human pathogens. Dis Model Mech (2008) 0.83
Abrogation of Age-Induced MicroRNA-195 Rejuvenates the Senescent Mesenchymal Stem Cells by Reactivating Telomerase. Stem Cells (2015) 0.83
The science and ethics of induced pluripotency: what will become of embryonic stem cells? Mayo Clin Proc (2011) 0.83
Self-assembled matrix by umbilical cord stem cells. J Funct Biomater (2011) 0.83
Transdifferentiation of peripheral blood mononuclear cells into epithelial-like cells. Am J Pathol (2007) 0.82
Stem cells and cell therapies for cystic fibrosis and other lung diseases. Pulm Pharmacol Ther (2007) 0.82
Stem cells and other innovative intra-articular therapies for osteoarthritis: what does the future hold? BMC Med (2012) 0.82
Perivascular mesenchymal stem cells in the adult human brain: a future target for neuroregeneration? Clin Transl Med (2012) 0.82
Lnk-dependent axis of SCF-cKit signal for osteogenesis in bone fracture healing. J Exp Med (2010) 0.81
Engineering stem cell niches in bioreactors. World J Stem Cells (2013) 0.81
A 3-D cardiac muscle construct for exploring adult marrow stem cell based myocardial regeneration. Biomaterials (2010) 0.81
Differentiation of bone marrow-derived cells into regenerated mesothelial cells in peritoneal remodeling using a peritoneal fibrosis mouse model. J Artif Organs (2012) 0.80
Identification of p63+ keratinocyte progenitor cells in circulation and their matrix-directed differentiation to epithelial cells. Stem Cell Res Ther (2013) 0.80
Hepatocyte nuclear factor-4alpha induces transdifferentiation of hematopoietic cells into hepatocytes. J Biol Chem (2009) 0.80
A degradable, bioactive, gelatinized alginate hydrogel to improve stem cell/growth factor delivery and facilitate healing after myocardial infarction. Med Hypotheses (2012) 0.80
Stem cell treatment of the heart: a review of its current status on the brink of clinical experimentation. Tex Heart Inst J (2005) 0.79
Distribution of cardiac stem cells in the human heart. ISRN Cardiol (2012) 0.79
On how Rac controls hematopoietic stem cell activity. Transfusion (2011) 0.79
Clinical application of stem cells for therapeutic angiogenesis in patients with peripheral arterial disease. Int J Stem Cells (2009) 0.79
Vascularization mediated by mesenchymal stem cells from bone marrow and adipose tissue: a comparison. Cell Regen (Lond) (2015) 0.79
Functional tooth regenerative therapy: tooth tissue regeneration and whole-tooth replacement. Odontology (2014) 0.79
The applications of bone marrow-derived stem cells to induce tolerance and chimerism in organ transplantation. Int J Organ Transplant Med (2010) 0.79
Exploring the stem cell and non-stem cell constituents of human breast milk. Cytotechnology (2012) 0.79
Transplantation of placenta-derived mesenchymal stem cells enhances angiogenesis after ischemic limb injury in mice. J Cell Mol Med (2015) 0.78
Apoptosis of bone marrow mesenchymal stem cells caused by homocysteine via activating JNK signal. PLoS One (2013) 0.78
Autologous stem cell transplantation in refractory Asherman's syndrome: A novel cell based therapy. J Hum Reprod Sci (2014) 0.78
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med (2010) 8.77
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell (2006) 8.59
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood (2006) 8.38
Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells. N Engl J Med (2002) 6.33
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood (2008) 4.61
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood (2006) 3.48
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst (2008) 2.77
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol (2010) 2.58
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol (2008) 2.54
STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood (2010) 2.48
Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. J Clin Oncol (2013) 2.42
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood (2012) 2.32
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature (2012) 2.28
Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res (2008) 2.17
Transdifferentiation of human peripheral blood CD34+-enriched cell population into cardiomyocytes, endothelial cells, and smooth muscle cells in vivo. Circulation (2003) 2.11
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood (2008) 2.04
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood (2004) 2.03
Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood (2002) 2.03
Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood (2014) 1.95
Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther (2008) 1.92
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood (2013) 1.87
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol (2009) 1.83
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood (2009) 1.82
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood (2009) 1.82
Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer (2008) 1.77
Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk Lymphoma (2014) 1.77
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood (2006) 1.73
Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia. Leuk Lymphoma (2014) 1.59
The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia. Cancer Res (2004) 1.55
WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res (2007) 1.49
Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis. Leuk Lymphoma (2013) 1.49
Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood (2006) 1.47
Both cell fusion and transdifferentiation account for the transformation of human peripheral blood CD34-positive cells into cardiomyocytes in vivo. Circulation (2004) 1.46
Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia. Leuk Res (2008) 1.45
The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood (2002) 1.45
Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood (2010) 1.43
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood (2013) 1.42
Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia. Leuk Res (2010) 1.42
Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome. Leuk Lymphoma (2006) 1.40
Myeloid neoplasms after breast cancer: "therapy-related" not an independent poor prognostic factor. Leuk Lymphoma (2014) 1.40
Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. Epigenetics (2010) 1.37
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer (2007) 1.37
Biphenotypic acute leukaemia: a case series. Br J Haematol (2007) 1.36
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood (2012) 1.34
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol (2008) 1.34
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood (2013) 1.33
Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res (2006) 1.25
Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies. Clin Cancer Res (2003) 1.24
Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood (2005) 1.23
OSW-1: a natural compound with potent anticancer activity and a novel mechanism of action. J Natl Cancer Inst (2005) 1.23
Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood (2005) 1.23
Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood (2002) 1.23
WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res (2008) 1.21
Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer (2011) 1.19
Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. Blood (2007) 1.18
CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia. Leuk Res (2002) 1.15
Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood (2007) 1.14
The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation. Cancer Sci (2008) 1.14
Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience. Int J Hematol (2009) 1.11
Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Cancer Res (2011) 1.10
Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood (2011) 1.10
Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood (2011) 1.09
Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. J Hematol Oncol (2009) 1.08
Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer (2010) 1.07
Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells. PLoS One (2010) 1.07
Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly. Blood (2012) 1.07
A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer (2011) 1.06
Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells. Mol Cancer (2013) 1.04
Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol (2010) 1.04
Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia. Blood (2003) 1.03
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leuk Res (2005) 1.00
Is acute myeloid leukemia a liquid tumor? Int J Cancer (2013) 0.99
STAT-3 activates NF-kappaB in chronic lymphocytic leukemia cells. Mol Cancer Res (2011) 0.98
Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Cancer (2014) 0.98
Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. J Clin Oncol (2011) 0.97
Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia. Hum Pathol (2004) 0.97
Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. Am J Hematol (2013) 0.96
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia. Am J Hematol (2013) 0.96
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol (2015) 0.95
Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remission. Br J Haematol (2002) 0.93
Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome. Clin Cancer Res (2009) 0.93
Aberrant morphology, proliferation, and apoptosis of B-cell chronic lymphocytic leukemia cells. Hematology (2004) 0.93
Potential role of activated platelets in homing of human endothelial progenitor cells to subendothelial matrix. Thromb Haemost (2006) 0.92
N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL). Leuk Res (2003) 0.92
Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. Br J Haematol (2013) 0.91
Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis. Transfusion (2006) 0.90
Circulating endothelial progenitor cells and coronary collaterals in patients with non-ST segment elevation myocardial infarction. J Vasc Res (2005) 0.89
Transformation of human mesenchymal cells and skin fibroblasts into hematopoietic cells. PLoS One (2011) 0.88
Clinical correlation of circulating heat shock protein 70 in acute leukemia. Leuk Res (2009) 0.88
Signal transducer and activator of transcription-3 induces microRNA-155 expression in chronic lymphocytic leukemia. PLoS One (2013) 0.88
Hematopoietic recovery following induction therapy of acute leukemias: prognostic implications and a new look at the definition of remission. Leuk Lymphoma (2004) 0.88
Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC. Blood (2010) 0.88
Ocular granulocytic sarcoma: a case report and literature review of ocular extramedullary acute myeloid leukemia. Clin Lymphoma Myeloma Leuk (2012) 0.88
AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer (2005) 0.88